Fig. 1From: A randomised study of the impact of the SGLT2 inhibitor dapagliflozin on microvascular and macrovascular circulationStudy design. Micro- and macrovascular parameters assessed at visits 0, 2, and 5. Clinical characteristics assessed at all visitsBack to article page